Literature DB >> 32130692

Tumor Microenvironment - Selective Pressures Boosting Cancer Progression.

Sofia C Nunes1,2.   

Abstract

In 2018, 9.6 million deaths from cancer were estimated, being this disease the second leading cause of death worldwide. Notwithstanding all the efforts developed in prevention, diagnosis and new treatment approaches, chemoresistance seems to be inevitable, leading to cancer progression, recurrence and affecting the outcome of the disease. As more and more evidence support that cancer is an evolutionary and ecological process, this concept is rarely applied in the clinical context. In fact, cancer cells emerge and progress within an ecological niche - the tumor microenvironment - that is shared with several other cell types and that is continuously changing. Therefore, the tumor microenvironment imposes several selective pressures on cancer cells such as acidosis, hypoxia, competition for space and resources, immune predation and anti-cancer therapies, that cancer cells must be able to adapt to or will face extinction.In here, the role of the tumor microenvironment selective pressures on cancer progression will be discussed, as well as the targeting of its features/components as strategies to fight cancer.

Entities:  

Keywords:  Cancer; Evolution; Metabolic selection; Microenvironment

Year:  2020        PMID: 32130692     DOI: 10.1007/978-3-030-34025-4_2

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  6 in total

Review 1.  Metabolomics in cancer research and emerging applications in clinical oncology.

Authors:  Daniel R Schmidt; Rutulkumar Patel; David G Kirsch; Caroline A Lewis; Matthew G Vander Heiden; Jason W Locasale
Journal:  CA Cancer J Clin       Date:  2021-05-13       Impact factor: 286.130

Review 2.  cGAS and cancer therapy: a double-edged sword.

Authors:  Jia-Min Du; Mei-Jia Qian; Tao Yuan; Rui-Han Chen; Qiao-Jun He; Bo Yang; Qi Ling; Hong Zhu
Journal:  Acta Pharmacol Sin       Date:  2022-01-18       Impact factor: 7.169

3.  Ocoxin Increases the Antitumor Effect of BRAF Inhibition and Reduces Cancer Associated Fibroblast-Mediated Chemoresistance and Protumoral Activity in Metastatic Melanoma.

Authors:  Aitor Benedicto; Iera Hernandez-Unzueta; Eduardo Sanz; Joana Márquez
Journal:  Nutrients       Date:  2021-02-21       Impact factor: 5.717

4.  Irinotecan/scFv co-loaded liposomes coaction on tumor cells and CAFs for enhanced colorectal cancer therapy.

Authors:  Zhaohuan Li; Chunxi Liu; Chenglei Li; Fangqing Wang; Jianhao Liu; Zengjuan Zheng; Jingliang Wu; Bo Zhang
Journal:  J Nanobiotechnology       Date:  2021-12-14       Impact factor: 10.435

5.  Identification of distinct slow mode of reversible adaptation of pancreatic ductal adenocarcinoma to the prolonged acidic pH microenvironment.

Authors:  Tzu-Chin Wu; Chien-Yu Liao; Wei-Chien Lu; Chuang-Rung Chang; Fang-Yu Tsai; Shih-Sheng Jiang; Tsung-Hsien Chen; Kurt Ming-Chao Lin; Li-Tzong Chen; Wun-Shaing Wayne Chang
Journal:  J Exp Clin Cancer Res       Date:  2022-04-11

6.  Survivin Splice Variant 2β Enhances Pancreatic Ductal Adenocarcinoma Resistance to Gemcitabine.

Authors:  Ryan N Fuller; Janviere Kabagwira; Paul A Vallejos; Andrew D Folkerts; Nathan R Wall
Journal:  Onco Targets Ther       Date:  2022-10-10       Impact factor: 4.345

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.